Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04050436
Recruitment Status : Recruiting
First Posted : August 8, 2019
Last Update Posted : July 21, 2022
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Replimune Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : March 2025